Gene therapy for bone healing: lessons learned and new approaches

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Orthopedic Research

Background:

• Gene therapy, initially for Mendelian disorders, shows promise for bone healing.
• Recombinant bone morphogenetic proteins (BMPs) like BMP-2 and -7 have osteogenic properties but face delivery challenges and modest efficacy.
• Current recombinant BMP delivery requires supraphysiological amounts, leading to side effects and high costs.

Purpose of the Study:

• To explore gene delivery as a strategy to overcome limitations of recombinant BMPs for bone healing.
• To investigate the efficacy and safety of delivering human BMP-2 cDNA for bone defect repair.
• To advance gene therapy for bone healing towards clinical application using novel delivery methods.

Main Methods:

• Focus on delivering cDNA encoding human BMP-2, leveraging existing FDA approval and clinical data.
• Utilized small animal models to assess intralesional delivery of BMP-2 cDNA.
• Current research explores genetically modified allografted cells and chemically modified messenger RNA for delivery.

Main Results:

• Intralesional delivery of BMP-2 cDNA demonstrated efficient and safe healing of bone defects in animal models.
• Achieved transient, local BMP-2 concentrations 2-3 log orders lower than those required by recombinant BMP-2.
• Confirmed the potential of gene delivery to overcome the limitations of recombinant protein therapy.

Conclusions:

• Gene delivery of BMP-2 cDNA is a viable strategy for bone healing, offering improved safety and efficacy over recombinant proteins.
• This approach significantly reduces the required protein concentrations, mitigating adverse effects and costs.
• Further research into novel delivery systems like modified cells and mRNA is crucial for clinical translation.